The estimated Net Worth of Roger Crystal is at least 7.58 百万$ dollars as of 27 January 2023. Roger Crystal owns over 1,358 units of Opiant Pharmaceuticals Inc stock worth over 1,555,750$ and over the last 6 years he sold OPNT stock worth over 608,515$. In addition, he makes 5,413,730$ as President、 Chief Executive Officer、 Director at Opiant Pharmaceuticals Inc.
Sign up
Roger Crystal OPNT stock SEC Form 4 insiders trading
Roger has made over 10 trades of the Opiant Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 1,358 units of OPNT stock worth 27,513$ on 27 January 2023.
The largest trade he's ever made was exercising 50,000 units of Opiant Pharmaceuticals Inc stock on 4 January 2019 worth over 331,500$. On average, Roger trades about 7,517 units every 93 days since 2019. As of 27 January 2023 he still owns at least 75,339 units of Opiant Pharmaceuticals Inc stock.
You can see the complete history of Roger Crystal stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Roger Crystal biography
Dr. Roger Crystal serves as President, Chief Executive Officer, Director of Lightlake Therapeutics Inc. He has an extensive background in healthcare, having worked as a surgeon in London’s leading hospitals, before transitioning into business. He has experience working in strategy healthcare consulting, serving across several functions in the UK National Health Service and with global pharmaceutical clients. He also has worked in business development with GE Healthcare since October 2010. In addition to his medical degree, he was awarded membership in The Royal College of Surgeons of England and holds an MBA from London Business School. He also has M&A experience at GE Capital and Goldman Sachs. He remains a UK board certified physician.
What is the salary of Roger Crystal?
As the President、 Chief Executive Officer、 Director of Opiant Pharmaceuticals Inc, the total compensation of Roger Crystal at Opiant Pharmaceuticals Inc is 5,413,730$. There are no executives at Opiant Pharmaceuticals Inc getting paid more.
How old is Roger Crystal?
Roger Crystal is 38, he's been the President、 Chief Executive Officer、 Director of Opiant Pharmaceuticals Inc since 2009. There are 9 older and no younger executives at Opiant Pharmaceuticals Inc. The oldest executive at Opiant Pharmaceuticals Inc is Michael Sinclair, 77, who is the Executive Chairman of the Board.
What's Roger Crystal's mailing address?
Roger's mailing address filed with the SEC is C/O OPIANT PHARMACEUTICALS, INC., 233 WILSHIRE BLVD, SUITE 400, SANTA MONICA, CA, 90401.
Insiders trading at Opiant Pharmaceuticals Inc
Over the last 21 years, insiders at Opiant Pharmaceuticals Inc have traded over 16,027,532$ worth of Opiant Pharmaceuticals Inc stock and bought 199,545 units worth 2,080,156$ . The most active insiders traders include Craig A Collard、Marc A Cohen、Alain J Cohen. On average, Opiant Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of 159,046$. The most recent stock trade was executed by Roger Crystal on 27 January 2023, trading 1,358 units of OPNT stock currently worth 27,513$.
What does Opiant Pharmaceuticals Inc do?
Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.
What does Opiant Pharmaceuticals Inc's logo look like?
Complete history of Roger Crystal stock trades at Opiant Pharmaceuticals Inc
Opiant Pharmaceuticals Inc executives and stock owners
Opiant Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Roger Crystal,
President, Chief Executive Officer, Director -
Michael Sinclair,
Executive Chairman of the Board -
Dr. Roger Crystal,
Pres, CEO & Director -
Dr. Phil Skolnick D.Sc. (hon), Ph.D.,
Chief Scientific Officer -
David D. O'Toole,
Chief Financial Officer -
Michael Porter,
IR Contact Officer -
Richard Daly,
Independent Director -
Craig Collard,
Independent Director -
Thomas Thomas,
Director -
Gabrielle Silver,
Director -
Ann MacDougall,
Director -
Aziz Mottiwala,
Chief Commercial Officer -
Rahsaan Thompson,
General Counsel -
Phil Skolnick,
Chief Scientific Officer -
Arvind Agrawal,
Executive Vice President - Medical Affairs -
David O'Toole,
Chief Financial Officer -
Matthew R. Ruth,
Chief Commercial Officer -
Dr. Mark Heath Ellison Ph.D.,
Chief Devel. Officer -
Brian Gorman,
EVP Corp. Devel. & Gen. Counsel -
Ben Atkins,
VP of Communications & Investor Relations -
Matthew R. Ruth,
Chief Commercial Officer -
Ronald W Kaiser,
Director -
Melvin Iii Wesley,
Chief Financial Officer -
William F Stasior,
Director -
Steven G Finn,
Director -
Joseph W Kuhn,
VP & Chief Financial Officer -
Alain J Cohen,
President & Chief Tech Officer -
Marc A Cohen,
Chairman, CEO, Treas, & Sec -
Brian Gorman,
-
Mark Jason Heath Ellison,
Chief Development Officer -
Masuoka K. Lorianne,
Director